Removal of phenytoin by hemodialysis in uremic patients.
The removal of phenytoin by hemodialysis was determined in seven uremic patients. Four patients were receiving phenytoin sodium for therapeutic purposes; three received one dose each intravenously to quantitate its disposition in uremia. The drug was measured in whole blood, plasma, saliva, and dialysate. Only 2% to 4% of the intravenous dose was recovered in the dialysate. Phenytoin clearance by dialysis was 7 to 14 ml/min; plasma clearance was 53 to 133 ml/min. Since hemodialysis contributes little toward shortening to 11-to-18-hour half-life of phenytoin in the uremic patients, no supplemental dose is necessary for uremic patients undergoing hemodialysis.
D000293:Adolescent; D000328:Adult; D004827:Epilepsy / Q000517:prevention & control; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D010949:Plasma / Q000032:analysis; D006435:Renal Dialysis; D012463:Saliva / Q000032:analysis; D012996:Solutions; D014511:Uremia / Q000150:complications*
D012996:Solutions; D010672:Phenytoin